Literature DB >> 22736508

Scalable syntheses of both enantiomers of DNJNAc and DGJNAc from glucuronolactone: the effect of N-alkylation on hexosaminidase inhibition.

Andreas F G Glawar1, Daniel Best, Benjamin J Ayers, Saori Miyauchi, Shinpei Nakagawa, Matilde Aguilar-Moncayo, José M García Fernández, Carmen Ortiz Mellet, Elizabeth V Crabtree, Terry D Butters, Francis X Wilson, Atsushi Kato, George W J Fleet.   

Abstract

The efficient scalable syntheses of 2-acetamido-1,2-dideoxy-D-galacto-nojirimycin (DGJNAc) and 2-acetamido-1,2-dideoxy-D-gluco-nojirimycin (DNJNAc) from D-glucuronolactone, as well as of their enantiomers from L-glucuronolactone, are reported. The evaluation of both enantiomers of DNJNAc and DGJNAc, along with their N-alkyl derivatives, as glycosidase inhibitors showed that DGJNAc and its N-alkyl derivatives were all inhibitors of α-GalNAcase but that none of the epimeric DNJNAc derivatives inhibited this enzyme. In contrast, both DGJNAc and DNJNAc, as well as their alkyl derivatives, were potent inhibitors of β-GlcNAcases and β-GalNAcases. Neither of the L-enantiomers showed any significant inhibition of any of the enzymes tested. Correlation of the in vitro inhibition with the cellular data, by using a free oligosaccharide analysis of the lysosomal enzyme inhibition, revealed the following structure-property relationship: hydrophobic side-chains preferentially promoted the intracellular access of iminosugars to those inhibitors with more-hydrophilic side-chain characteristics.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736508     DOI: 10.1002/chem.201200110

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

1.  sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease.

Authors:  Manuel González-Cuesta; Irene Herrera-González; M Isabel García-Moreno; Roger A Ashmus; David J Vocadlo; José M García Fernández; Eiji Nanba; Katsumi Higaki; Carmen Ortiz Mellet
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Pharmacological chaperones for human α-N-acetylgalactosaminidase.

Authors:  Nathaniel E Clark; Matthew C Metcalf; Daniel Best; George W J Fleet; Scott C Garman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

3.  A crystal structure-guided rational design switching non-carbohydrate inhibitors' specificity between two β-GlcNAcase homologs.

Authors:  Tian Liu; Peng Guo; Yong Zhou; Jing Wang; Lei Chen; Huibin Yang; Xuhong Qian; Qing Yang
Journal:  Sci Rep       Date:  2014-08-26       Impact factor: 4.379

4.  Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes.

Authors:  Andrew C Sayce; Dominic S Alonzi; Sarah S Killingbeck; Beatrice E Tyrrell; Michelle L Hill; Alessandro T Caputo; Ren Iwaki; Kyoko Kinami; Daisuke Ide; J L Kiappes; P Robert Beatty; Atsushi Kato; Eva Harris; Raymond A Dwek; Joanna L Miller; Nicole Zitzmann
Journal:  PLoS Negl Trop Dis       Date:  2016-03-14

5.  Synthesis of Pyrrolidine Monocyclic Analogues of Pochonicine and Its Stereoisomers: Pursuit ofSimplified Structures and Potent β-N-Acetylhexosaminidase Inhibition.

Authors:  Xin Yan; Yuna Shimadate; Atsushi Kato; Yi-Xian Li; Yue-Mei Jia; George W J Fleet; Chu-Yi Yu
Journal:  Molecules       Date:  2020-03-25       Impact factor: 4.411

6.  Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.

Authors:  Kelly L Warfield; Emily M Plummer; Andrew C Sayce; Dominic S Alonzi; William Tang; Beatrice E Tyrrell; Michelle L Hill; Alessandro T Caputo; Sarah S Killingbeck; P Robert Beatty; Eva Harris; Ren Iwaki; Kyoko Kinami; Daisuke Ide; J L Kiappes; Atsushi Kato; Michael D Buck; Kevin King; William Eddy; Mansoora Khaliq; Aruna Sampath; Anthony M Treston; Raymond A Dwek; Sven G Enterlein; Joanna L Miller; Nicole Zitzmann; Urban Ramstedt; Sujan Shresta
Journal:  Antiviral Res       Date:  2016-03-03       Impact factor: 10.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.